US › Healthcare

Can Fite Biopharma Ltd ADR (CANF)

US · Healthcare · Biotechnology

$3.19+0.63%

Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue

$101,500

Revenue YoY

-43.3%

Net profit

$-2.5M

Profit YoY

-26.2%

EPS

$0.00

EPS estimate

$-2.40

Net margin

-2,439.4%

EPS came in at 0.00 against a street estimate of -2.40 — a beat of 100.0%.

Key statistics

Market cap

$6.7M

Forward P/E

3.0

P/B

1.21

Book value

$4.27

EPS (TTM)

$-10.75

52-week high

$14.06

52-week low

$2.56

50-day MA

$3.22

200-day MA

$4.58

Beta

0.02

Analyst view

Analysts rate Can Fite Biopharma Ltd ADR a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $8.00.

Shareholding

Institutions

6.55%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Can Fite Biopharma Ltd ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.